Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Phase I Placebo Controlled, Dose Escalation Study Assessing the Ocular and Systemic Safety and Tolerability of OC-10X

NCT01869933 is registered in ClinicalTrials.gov with OcuCure Therapeutics, Inc. as lead sponsor.

NCT NCT01869933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01869933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Phase I Placebo Controlled, Dose Escalation Study Assessing the Ocular and Systemic Safety and Tolerability of OC-10X
Lead sponsor
OcuCure Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2013
Completion date
June 30, 2013
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

proliferative diabetic retinopathy (pdr)